Halting ionic shuttle to disrupt the synthetic machinery-Structural and molecular insights into the inhibitory roles of Bedaquiline towards Mycobacterium tuberculosis ATP synthase in the treatment of tuberculosis.
Autor: | Salifu EY; Molecular Bio-computation and Drug Design Laboratory, Discipline of Pharmaceutical Chemistry, University of KwaZulu-Natal, Westville Campus, Durban, South Africa., Agoni C; Molecular Bio-computation and Drug Design Laboratory, Discipline of Pharmaceutical Chemistry, University of KwaZulu-Natal, Westville Campus, Durban, South Africa., Olotu FA; Molecular Bio-computation and Drug Design Laboratory, Discipline of Pharmaceutical Chemistry, University of KwaZulu-Natal, Westville Campus, Durban, South Africa., Dokurugu YM; College of Pharmacy & Pharmaceutical Sciences, Institute of Public Health, Florida Agricultural & Mechanical University, Tallahassee, Florida., Soliman MES; Molecular Bio-computation and Drug Design Laboratory, Discipline of Pharmaceutical Chemistry, University of KwaZulu-Natal, Westville Campus, Durban, South Africa. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of cellular biochemistry [J Cell Biochem] 2019 Sep; Vol. 120 (9), pp. 16108-16119. Date of Electronic Publication: 2019 May 24. |
DOI: | 10.1002/jcb.28891 |
Abstrakt: | Therapeutic targeting of the adenosine triphosphate (ATP) machinery of Mycobacterium tuberculosis (Mtb) has recently presented a potent and alternative measure to halt the pathogenesis of tuberculosis. This has been potentiated by the development of bedaquiline (BDQ), a novel small molecule inhibitor that selectively inhibits mycobacterial F (© 2019 Wiley Periodicals, Inc.) |
Databáze: | MEDLINE |
Externí odkaz: |